Edesa Biotech, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended March 31, 2021 (fiscal second quarter and first half). The company is a clinical-stage biopharmaceutical developer focused on inflammatory and immune-related diseases. Financial statements are unaudited and presented in U.S. dollars.
Financial results and liquidity
- Revenue: No product sales in either the quarter or first half, versus $110,516 and $218,316, respectively, in 2020, as legacy product sales were discontinued.
- Grant income: Recognized $7.17 million in the quarter and first half from the Canadian Strategic Innovation Fund (SIF). The same amount was included in receivables at March 31; it is not reported as cash received.
- Expenses and losses: First-half operating expenses were $12.12 million, including $9.35 million R&D and $2.77 million general and administrative. Net loss was $4.90 million, or $0.45 per share, versus $2.58 million, or $0.32 per share, in the first half of 2020. Second-quarter net loss was $2.26 million, or $0.19 per share, versus $1.49 million, or $0.17 per share.
- Cash flow: First-half operating cash use was $10.19 million, compared with $1.96 million in 2020. Financing provided $13.94 million, principally from equity offerings and warrant exercises. Cash increased by $3.75 million to $10.97 million.
- Balance sheet: At March 31, cash was $10.97 million, working capital $16.80 million, total assets $24.00 million, total liabilities $4.73 million, and shareholders’ equity $19.27 million. The company reported no borrowing debt; liabilities included $4.54 million of accounts payable and accrued liabilities and $138,137 of lease liabilities.
- Margins: Not meaningful given no current-period product sales.
Changes versus comparable periods
- First-half R&D expense rose from $1.03 million to $9.35 million, mainly due to EB05 clinical-program milestone payments, increased clinical and investigational-product activity, and share-based compensation. The quarter included a $3.5 million license milestone expense.
- First-half G&A increased from $1.80 million to $2.77 million, reflecting higher personnel, share-based compensation, headcount, legal and professional costs.
- Grant income substantially offset higher operating expenses, but the company still reported a larger net loss. First-half share-based compensation rose to $1.19 million from $389,000.
- Common shares outstanding increased to 13,246,559 at March 31 from 9,615,119 at September 30, 2020. The March public offering generated $10.0 million gross proceeds; the company reported estimated net proceeds of $8.85 million.
Outlook, risks and unusual items
- Management said it plans to fund operations over the next 12 months using cash on hand and SIF reimbursements, while retaining flexibility to adjust spending. It may seek additional equity, grants, debt, licensing or other financing; availability and terms are not assured.
- The SIF agreement provides up to C$14.05 million (approximately US$11 million) toward specified EB05 study and preclinical costs, with reimbursement of 75% of eligible expenses through claims. Edesa must first incur and fund those costs. Breach may lead to suspended or terminated funding or repayment demands; the company guarantees its subsidiary’s obligations.
- As of May 12, more than 285 patients had been randomized in the EB05 Phase 2/3 study; the Phase 2 portion could enroll up to 396. EB01’s first 46-patient Phase 2b cohort had completed treatment, with blinded interim data under analysis as of the filing’s update.
- License agreements carry substantial contingent exposure: up to $352.5 million in future milestone payments for the Constructs, up to $69.2 million under a March 2021 license, and up to $18.6 million under an earlier license. These are contingent amounts, primarily tied to future development, approval and sales milestones, not current liabilities. Research and other contracted commitments totaled $5.05 million at March 31.
- COVID-19 may affect operations, clinical timelines and results. The company also disclosed unhedged Canadian-dollar exposure: a 10% annual exchange-rate change was estimated to affect loss and comprehensive loss by approximately $1.45 million.
- Management reported effective disclosure controls as of March 31 and no material change in internal control over financial reporting. No material legal proceedings outside the ordinary course were reported; no material risk-factor changes were identified.
Key facts for investors to verify
- Timing and collection of the $7.17 million SIF receivable, and remaining eligible reimbursement capacity and conditions.
- EB05 and EB01 enrollment, interim and final study results, timelines, and related spending.
- Cash burn, contracted commitments, and management’s 12-month funding plan as trial costs evolve.
- Potential dilution from further financing, outstanding warrants and options, and the increased equity-plan share reserve.
- Terms and likelihood of future license milestones, royalties, and any additional funding or repayment obligations under the SIF agreement.